It has been reported that Tanespimycin is a classical inhibitor of Hsp90 (34), and Runx2 is transcriptionally regulated by Hsp90 through the AKT/gsk-3/catenin signaling pathway, leading to apoptosis of osteosarcoma cells (35). This evidence concerns the gene RUNX2 and osteosarcoma.